Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Liver Diseases, Alcoholic Clinical Trial

Official title:

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03388320
• Other study ID #: 1704018122
• Status: Recruiting
• Phase: N/A
• Start date: April 24, 2018
• Est. completion date: December 1, 2021

Study information

• Verified date: March 2019
• Source: New York Presbyterian Hospital
• Contact: Nicole T Shen, MD
• Phone: 3146095911
• Email: nts9004[@]nyp.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study examining whether an evidence-based recovery support smartphone application, the Addiction Comprehensive Health Enhancement Support System (A-CHESS), can decrease alcohol recidivism in a previously unstudied group of patients with alcoholic liver disease (ALD).

Description:

A-CHESS is a smartphone application developed by the University of Wisconsin-Madison based on self-determination theory, with a previous randomized clinical trial showing that use of the app resulted in significantly fewer risky drinking days in patients leaving treatment for alcohol-use disorders. The application is downloaded to the participant's smartphone, and provides ongoing access to peer support and educational materials, monitoring of the risk of relapse, and delivery of reminders and encouragements to the patient. The application also has a survey platform to assess and reassess the participants' most recent alcohol consumption, quality of life, and experience using the application. We anticipate that use of the A-CHESS app will result in decreased drinking and improved abstinence, identifying a potential intervention to offer patients with ALD to improve their mortality, liver disease, and likelihood of liver transplant candidacy status.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 1, 2021
• Est. primary completion date: January 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Alcoholic liver disease

• Followed or seen at New York Presbyterian Hospital / Weill Cornell Medical Center

• English speaking

• Access to a smartphone

Exclusion Criteria:

• Unable to consent

• Primary language other than English

• No access to a smartphone

Related Conditions & MeSH terms

• Liver Diseases
• Liver Diseases, Alcoholic

Intervention

Device:
• A-CHESS
Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)

Locations

Country	Name	City	State
United States	New York Presbyterian Hospital - Weill Cornell Medicine and Columbia University Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York Presbyterian Hospital	University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rates of recidivism	Rates of recidivism in this population using A-CHESS will be compared to historical control rates	6 months
Secondary	Use of A-CHESS	The association between the extent to which patients use the A-CHESS application and their recidivism; to compare use of the A-CHESS app among subjects who drink and remain abstinent.	6 months